These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 11178117

  • 1. The human exosome: an autoantigenic complex of exoribonucleases in myositis and scleroderma.
    Brouwer R, Pruijn GJ, van Venrooij WJ.
    Arthritis Res; 2001; 3(2):102-6. PubMed ID: 11178117
    [Abstract] [Full Text] [Related]

  • 2. Autoantibodies directed to novel components of the PM/Scl complex, the human exosome.
    Brouwer R, Vree Egberts WT, Hengstman GJ, Raijmakers R, van Engelen BG, Seelig HP, Renz M, Mierau R, Genth E, Pruijn GJ, van Venrooij WJ.
    Arthritis Res; 2002; 4(2):134-8. PubMed ID: 11879549
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The human exosome and disease.
    Staals RH, Pruijn GJ.
    Adv Exp Med Biol; 2010; 702():132-42. PubMed ID: 21618880
    [Abstract] [Full Text] [Related]

  • 5. PM1-Alpha ELISA: the assay of choice for the detection of anti-PM/Scl autoantibodies?
    Mahler M, Fritzler MJ.
    Autoimmun Rev; 2009 Mar; 8(5):373-8. PubMed ID: 19103309
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome.
    Raijmakers R, Renz M, Wiemann C, Egberts WV, Seelig HP, van Venrooij WJ, Pruijn GJ.
    Arthritis Rheum; 2004 Feb; 50(2):565-9. PubMed ID: 14872500
    [Abstract] [Full Text] [Related]

  • 9. Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations.
    Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger TA.
    Arthritis Rheum; 1992 Oct; 35(10):1211-7. PubMed ID: 1418007
    [Abstract] [Full Text] [Related]

  • 10. C1D is a major autoantibody target in patients with the polymyositis-scleroderma overlap syndrome.
    Schilders G, Egberts WV, Raijmakers R, Pruijn GJ.
    Arthritis Rheum; 2007 Jul; 56(7):2449-54. PubMed ID: 17599775
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort.
    Lazzaroni MG, Marasco E, Campochiaro C, DeVries-Bouwstra J, Gonzalez-Perez MI, Rojas-Serrano J, Hachulla E, Zanatta E, Barsotti S, Furini F, Triantafyllias K, Abignano G, Truchetet ME, De Luca G, De Langhe E, Hesselstrand R, Ingegnoli F, Bertoldo E, Smith V, Bellando-Randone S, Poormoghim H, Colombo E, Ceribelli A, Furloni A, Zingarelli S, Cavazzana I, Franceschini F, Del Galdo F, Denton CP, Cavagna L, Distler O, Allanore Y, Airò P, EUSTAR co-authors.
    Rheumatology (Oxford); 2021 Nov 03; 60(11):5028-5041. PubMed ID: 33580257
    [Abstract] [Full Text] [Related]

  • 13. Scleroderma/polymyositis overlap syndromes and their immunologic markers.
    Jablonska S, Chorzelski TP, Blaszczyk M, Jarzabek-Chorzelska M, Kumar V, Beutner EH.
    Clin Dermatol; 1992 Nov 03; 10(4):457-72. PubMed ID: 1303810
    [No Abstract] [Full Text] [Related]

  • 14. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients.
    Hanke K, Brückner CS, Dähnrich C, Huscher D, Komorowski L, Meyer W, Janssen A, Backhaus M, Becker M, Kill A, Egerer K, Burmester GR, Hiepe F, Schlumberger W, Riemekasten G.
    Arthritis Res Ther; 2009 Nov 03; 11(1):R22. PubMed ID: 19220911
    [Abstract] [Full Text] [Related]

  • 15. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl.
    Marguerie C, Bunn CC, Copier J, Bernstein RM, Gilroy JM, Black CM, So AK, Walport MJ.
    Medicine (Baltimore); 1992 Nov 03; 71(6):327-36. PubMed ID: 1435228
    [Abstract] [Full Text] [Related]

  • 16. [Anti PM-Scl antibodies. Study of prevalence and of meaning].
    Gaudin C, Fortenfant F, Adoue D, Beyne-Rauzy O.
    Rev Med Interne; 2006 Sep 03; 27(9):665-70. PubMed ID: 16797795
    [Abstract] [Full Text] [Related]

  • 17. Analysis of the specificity of anti-PM-Scl autoantibodies.
    Ge Q, Wu Y, Trieu EP, Targoff IN.
    Arthritis Rheum; 1994 Oct 03; 37(10):1445-52. PubMed ID: 7945469
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Anti-PM/Scl-100 and anti-RNA-polymerase III antibodies in scleroderma.
    Maes L, Blockmans D, Verschueren P, Westhovens R, De Beéck KO, Vermeersch P, Van den Bergh K, Burlingame RW, Mahler M, Bossuyt X.
    Clin Chim Acta; 2010 Jul 04; 411(13-14):965-71. PubMed ID: 20346932
    [Abstract] [Full Text] [Related]

  • 20. Anti-PM-Scl antibody in patients with systemic sclerosis.
    Koschik RW, Fertig N, Lucas MR, Domsic RT, Medsger TA.
    Clin Exp Rheumatol; 2012 Jul 04; 30(2 Suppl 71):S12-6. PubMed ID: 22261302
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.